Published November 27, 2019 | Version v1
Project deliverable Open

D2.6 Participating vertical industries planning

  • 1. ORANGE SA
  • 2. WINGS ICT Solutions
  • 3. Nokia Solutions and Networks Hellas S.A
  • 4. Hellenic Telecommunications Organisation S.A
  • 5. B-COM
  • 6. Nokia, France
  • 7. Eurecom
  • 8. FSTechnology SpA
  • 9. Universidad Carlos III de Madrid
  • 10. IMDEA
  • 11. Ericsson España S.A
  • 12. Ericsson Telecomunicazioni S.p.A
  • 13. Applied research to technologies
  • 14. Telecom Italia
  • 15. NEXTWORKS S.r.l.
  • 16. Città di Torino
  • 17. Consorzio Nazionale Interuniversitario per le Telecomunicazioni
  • 18. Eurescom GmbH

Description

The present deliverable aims at giving the planning of the integration, test and validation of the different verticals in the 5G EVE facility. First, an overview of the 5G EVE E2E facility is given through the status of the 4 sites facilities focusing on their main updates since their description carried out in [2]. Then, we mainly detail the planning of the internal 5G EVE verticals before introducing the external ones. The internal 5G EVE verticals have already been described, as well as their KPIs in [1]. A very short summary of each of them is proposed, sometimes giving also some preliminary performance results obtained during first experimentation (most often achieved in lab) and mostly providing the roadmap of their integration, test and validation in the 5G EVE facility. The external verticals are issued from the ICT-19 and ICT-22 projects that have expressed their interests to use the 5G EVE facility to experiment their use-cases. So, a short description of the ICT-19/22 projects is carried out by detailing their respective use-cases they want to integrate. For each use-case, the KPIs and main features requested are detailed. Then, a tentative planning is proposed for each external vertical.

Files

5g-eve-d2.6-participating-vertical-industries-planning.pdf

Files (7.8 MB)

Additional details

Funding

5G EVE – 5G European Validation platform for Extensive trials 815074
European Commission